Why the study?
Little is known about the prognostic implications of early LVEF improvement as a sole predictor of outcomes after TAVR.
Does early LVEF improvement after TAVR improve 5-year outcomes in patients with reduced LVEF?
Does early LVEF improvement after TAVR improve 5-year outcomes in patients with reduced LVEF?
In patients undergoing TAVR, early improvement in LVEF at 30 days is associated with a lower rate of MACE at 5 years, although it does not significantly impact 5-year all-cause mortality.
LVEF improvement after TAVR was not linked to lower 5-year mortality; leaves open its prognostic value for MACE in observational cohorts.
Introduction Transcatheter aortic valve replacement (TAVR) has become an efficient and save alternative to surgical aortic valve replacement (SAVR). While severe aortic stenosis as well as severe aortic regurgitation (AR) is known to negatively impact left ventricular ejection fraction (LVEF), prior studies have shown that TAVR can lead to improvement in LVEF. So far, little is known about the prognostic implication of LVEF-improvement as a sole predictor of outcomes. Purpose The aim of this study was to assess the prognostic significance of early LVEF improvement in patients undergoing TAVR. Materials and Methods Patients undergoing TAVR in a large tertiary university hospital have been consecutively included in a large prospective registry. Transthoracic echocardiography (TTE) was performed at baseline, after TAVR before discharge, at 1 month and annually thereafter. Significant LVEF improvement was defined as >10% relative increase of LVEF at 30 days compared to baseline LVEF. Primary outcome was all-cause mortality at 5 years. Secondary outcome were major adverse cardiovascular events (MACE), including death, non-fatal myocardial infarction, stroke, bleeding and unplanned re-interventions of the aortic valve. Results Among 1481 patients undergoing TAVR between September 2011 and June 2023, LVEF at baseline and at 30 days was available in 1013 patients. 665 patients (65.6%) had normal LVEF at baseline, whereas 348 patients (34.4%) had a reduced LVEF. Of these, 137 patients (13.5%) showed significant improvement of LVEF ≥10%) after 30 days, while 266 patients (26.3%) showed no significant LVEF-improvement (<10%). The combined patients with persevered LVEF at baseline had significantly better outcomes than those with impaired EF (p=<0.001). LVEF improvement was not associated with mortality at 5 years (p= 0.51), however with lower MACE rate at 5 years (p=0,024). Conclusion Normal LVEF before TAVR is an independent predictor for improved outcomes. In addition, early improvement of LVEF is associated with beneficial outcomes in patients undergoing TAVR.Course of LVEF after TAVROutcomes after TAVR
No takes yet. Share an insight, caveat, or question.
Reichl et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: